Semi-synthesis of small molecules of aminocarbazoles: tumor growth inhibition and potential impact on p53

• Autor(a) principal: Long, Solida
• Data de Publicação: 2021
• Outros Autores: Loureiro, Joana B., Carvalho, Carla, Gales, Luís, Saraiva, Lucília, Pinto, Madalena M. M., Puthongking, Ploenthip, Sousa, Emília
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/1822/73355
• topic: Aminocarbazoles; Heptaphylline; Alkaloids; Tumor; p53; Mutant

The tumor suppressor p53 is inactivated by mutation in approximately 50% of human cancers. Small molecules that bind and stabilize those mutants may represent effective anticancer drugs. Herein, we report the tumor cell growth inhibitory activity of carbazole alkaloids and amino derivatives, as well as their potential activation of p53. Twelve aminocarbazole alkaloids were semi-synthesized from heptaphylline (<b>1</b>), 7-methoxy heptaphylline (<b>2</b>), and 7-methoxymukonal (<b>3</b>), isolated from <i>Clausena harmandiana</i>, using a reductive amination protocol. Naturally-occurring carbazoles 1–3 and their amino derivatives were evaluated for their potential effect on wild-type and mutant p53 activity using a yeast screening assay and on human tumor cell lines. Naturally-occurring carbazoles 1–3 showed the most potent growth inhibitory effects on wild-type p53-expressing cells, being heptaphylline (<b>1</b>) the most promising in all the investigated cell lines. However, compound <b>1</b> also showed growth inhibition against non-tumor cells. Conversely, semi-synthetic aminocarbazole 1d showed an interesting growth inhibitory activity in tumor cells expressing both wild-type and mutant p53, exhibiting low growth inhibition on non-tumor cells. The yeast assay showed a potential reactivation of mutant p53 by heptaphylline derivatives, including compound <b>1d</b>. The results obtained indicate that carbazole alkaloids may represent a promising starting point to search for new mutp53-reactivating agents with promising applications in cancer therapy.